Foghorn Therapeutics (FHTX) EBT (2019 - 2026)
Foghorn Therapeutics (FHTX) recorded quarterly EBT of -$19.8 million in Q1 2026, up 10.53% quarter-over-quarter from -$22.2 million in Q4 2025, and up 1.93% on a YoY basis from -$19.5 million in Q1 2025.
Foghorn Therapeutics (FHTX) EBT (2019 - 2026) Analysis & Trends
Foghorn Therapeutics' EBT history runs 8 years deep, the most recent figure standing at -$19.8 million for Q1 2026.
- In Q1 2026, EBT rose 1.93% year-over-year to -$19.8 million; the TTM figure through Mar 2026 stood at -$77.3 million (up 5.59% YoY), while the FY2025 annual figure was -$77.6 million, up 10.36% from the prior year.
- EBT was -$19.8 million for Q1 2026 at Foghorn Therapeutics, up from -$22.2 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$13.6 million in Q3 2023 to a low of -$29.9 million in Q1 2023.
- Historically, EBT has averaged -$22.8 million across 5 years, with a median of -$22.2 million in 2025.
- The sharpest annual moves came in 2023 and 2024: EBT jumped 47.2% in 2023, then slumped 40.53% in 2024.
- A 5-year view of EBT shows it stood at -$28.9 million in 2022, then gained by 23.42% to -$22.1 million in 2023, then advanced by 11.83% to -$19.5 million in 2024, then decreased by 13.65% to -$22.2 million in 2025, then climbed by 10.53% to -$19.8 million in 2026.
- The last three EBT figures came in at -$19.8 million (Q1 2026), -$22.2 million (Q4 2025), and -$16.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.18 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.31 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | -19.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.83 Mn |
| Dec 31, 2025 | -22.17 Mn |
| Sep 30, 2025 | -16.47 Mn |
| Jun 30, 2025 | -18.79 Mn |
| Mar 31, 2025 | -20.22 Mn |
| Dec 31, 2024 | -19.50 Mn |
| Sep 30, 2024 | -19.12 Mn |
| Jun 30, 2024 | -22.98 Mn |
| Mar 31, 2024 | -25.02 Mn |
| Dec 31, 2023 | -22.12 Mn |
| Sep 30, 2023 | -13.61 Mn |
| Jun 30, 2023 | -28.55 Mn |
| Mar 31, 2023 | -29.93 Mn |
| Dec 31, 2022 | -28.89 Mn |
| Sep 30, 2022 | -25.77 Mn |
| Jun 30, 2022 | -27.31 Mn |
| Mar 31, 2022 | -26.91 Mn |
| Dec 31, 2021 | -28.51 Mn |
| Sep 30, 2021 | -26.76 Mn |
| Jun 30, 2021 | -23.76 Mn |